Parexel Adds Clinical Development Optimization
Parexel has enhanced its end-to-end clinical development services through its new Clinical Development Optimization process, which uses advanced technology to help expedite drug development through all four critical stages of clinical development – design, start-up, trial execution, and submission.
- Design: Protocol design optimization uses simulations to allow sponsors to identify and quantify the impact of trade-off decisions on program performance, timelines and cost.
- Start-up: Site start-up, Clinical Trial Management System, and electronic Trial Master File integrated applications provide efficient distribution, collaborative compilation and e-signing of site-level regulatory documents and contracts. Clinical Trial Supplies & Logistics handles supply chain challenges and optimizes supply levels.
- Execute: Intelligent technology from the PAREXEL Informatics product line helps predict and capture core operational and scientific data.
- Submit: Data aggregation aligned with commercial decision-making strategy can help ensure the right technology and operational support for an initial regulatory application, identification of future opportunities, and product lifecycle management.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
